Medical cannabis: Mechanisms of action and therapeutic targets
DOI:
https://doi.org/10.12775/JEHS.2024.58.013Keywords
medical marihuana, medical cannabis, medical marihuana mechanism of action, therapeutic targets of medical marihuana, endocannabinoid system, medical marihuana in pain treatment, medical marihuana amygdala body, medical marihuana serotonin receptorsAbstract
Introduction: In recent years, multiple publications underscored many beneficial properties associated with medical marihuana. Its current applications encompass pain relief, multiple sclerosis, the treatment of anxiety disorders, Dravet syndrome and other. It can potentially extent to the treatment of patients with fibromyalgia or in people with diabetic complications. The expansive potential of medical cannabis in the prevention and treatment of many diseases is seen in its complex and multidirectional mechanisms of action. Medical marihuana has impact on cannabinoid receptors, and it exerts effects through many other molecular targets.
Aim of the study: This review seeks present mechanisms of action of medical marihuana and explore its potential therapeutic targets.
Materials and methods: A comprehensive review of literature available in the PubMed and Google Scholar databases was performed, using the following keywords: "medical marihuana", "medical cannabis", "medical marihuana mechanism of action", "therapeutic targets of medical marihuana", "endocannabinoid system", “medical marihuana in pain treatment”, “medical marihuana amygdala body”, “medical marihuana serotonin receptors”.
Conclusions: Medical marihuana emerges as a promising candidate in the treatment of many diseases and common condition. However, further research is imperative to ascertain the effects of the drug and transform it into an effective medication which maximizes benefits and minimalizes side effects.
References
Lal S, Shekher A, Puneet, Narula AS, Abrahamse H, Gupta SC. Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities. Pharmacol Res. 2021;163:105302. doi:10.1016/j.phrs.2020.105302
Ebbert JO, Scharf EL, Hurt RT. Medical Cannabis. Mayo Clin Proc. 2018;93(12):1842-1847. doi:10.1016/j.mayocp.2018.09.005
Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol (Δ8 -THC): Comparative pharmacology with Δ9 -THC [published correction appears in Br J Pharmacol. 2023 Jan;180(1):130]. Br J Pharmacol. 2022;179(15):3915-3933. doi:10.1111/bph.15865
Dharmapuri S, Miller K, Klein JD. Marijuana and the Pediatric Population. Pediatrics. 2020;146(2):e20192629. doi:10.1542/peds.2019-2629
Gupta K, Walton R, Kataria SP. Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer Treat Res Commun. 2021;26:100278. doi:10.1016/j.ctarc.2020.100278
Crocq MA. History of cannabis and the endocannabinoid system . Dialogues Clin Neurosci. 2020;22(3):223-228. doi:10.31887/DCNS.2020.22.3/mcrocq
Charitos IA, Gagliano-Candela R, Santacroce L, Bottalico L. The Cannabis Spread throughout the Continents and its Therapeutic Use in History. Endocr Metab Immune Disord Drug Targets. 2021;21(3):407-417. doi:10.2174/1871530320666200520095900
Amin MR, Ali DW. Pharmacology of Medical Cannabis. Adv Exp Med Biol. 2019;1162:151-165. doi:10.1007/978-3-030-21737-2_8
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. doi:10.1038/sj.bjp.0707442
Nachnani R, Raup-Konsavage WM, Vrana KE. The Pharmacological Case for Cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. doi:10.1124/jpet.120.000340
Di Marzo V, Piscitelli F. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics. 2015;12(4):692-698. doi:10.1007/s13311-015-0374-6
Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607-615. doi:10.1016/j.bpsc.2020.07.016
Biernacki M, Skrzydlewska E. Metabolism of endocannabinoids. Postepy Hig Med Dosw (Online). 2016;70(0):830-843. Published 2016 Aug 11. doi:10.5604/17322693.1213898
De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479-1494. doi:10.1111/j.1476-5381.2010.01166.x
Mock ED, Gagestein B, van der Stelt M. Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. Prog Lipid Res. 2023;89:101194. doi:10.1016/j.plipres.2022.101194
Singh D, Lippmann S. Vaping medical marijuana. Postgrad Med. 2018;130(2):183-185. doi:10.1080/00325481.2018.1413281
Wennberg E, Windle SB, Filion KB, et al. Roadside screening tests for cannabis use: A systematic review. Heliyon. 2023;9(4):e14630. Published 2023 Mar 22. doi:10.1016/j.heliyon.2023.e14630
Potschka H, Bhatti SFM, Tipold A, McGrath S. Cannabidiol in canine epilepsy. Vet J. 2022;290:105913. doi:10.1016/j.tvjl.2022.105913
Potschka H, Bhatti SFM, Tipold A, McGrath S. Cannabidiol in canine epilepsy. Vet J. 2022;290:105913. doi:10.1016/j.tvjl.2022.105913
Xiong W, Koo BN, Morton R, Zhang L. Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism. Neuroscience. 2011;184:28-37. doi:10.1016/j.neuroscience.2011.03.066
Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10-15. doi:10.1684/epd.2020.1135
Alexander C, Vasefi M. Cannabidiol and the corticoraphe circuit in post-traumatic stress disorder. IBRO Neurosci Rep. 2021;11:88-102. Published 2021 Aug 21. doi:10.1016/j.ibneur.2021.08.001
Rosenberg EC, Chamberland S, Bazelot M, et al. Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity. Neuron. 2023;111(8):1282-1300.e8. doi:10.1016/j.neuron.2023.01.018
Rodrigues Tavares, L. R., Baptista-de-Souza, D., Canto-de-Souza, L., Planeta, C. D. S., Guimarães, F. S., Nunes-de-Souza, R. L., & Canto-de-Souza, A. (2023). The Reversal of Empathy-Induced Hypernociception in Male Mice by Intra-Amygdala Administration of Midazolam and Cannabidiol Depends on 5-HT3 Receptors. Cannabis and cannabinoid research, 8(2), 335–347. https://doi.org/10.1089/can.2022.0132 - 5ht3
Kowalski CW, Ragozzino FJ, Lindberg JEM, et al. Cannabidiol activation of vagal afferent neurons requires TRPA1. J Neurophysiol. 2020;124(5):1388-1398. doi:10.1152/jn.00128.2020
Louis-Gray K, Tupal S, Premkumar LS. TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids. Int J Mol Sci. 2022;23(17):10016. Published 2022 Sep 2. doi:10.3390/ijms231710016
Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10-15. doi:10.1684/epd.2020.1135
Mottarlini F, Fumagalli M, Castillo-Díaz F, et al. Single and Repeated Exposure to Cannabidiol Differently Modulate BDNF Expression and Signaling in the Cortico-Striatal Brain Network. Biomedicines. 2022;10(8):1853. Published 2022 Aug 1. doi:10.3390/biomedicines10081853
Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. Int J Mol Sci. 2022;23(6):3344. Published 2022 Mar 19. doi:10.3390/ijms23063344
Lee G, Grovey B, Furnish T, Wallace M. Medical Cannabis for Neuropathic Pain. Curr Pain Headache Rep. 2018;22(1):8. Published 2018 Feb 1. doi:10.1007/s11916-018-0658-8
Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease. Front Pharmacol. 2020;11:595635. Published 2020 Dec 15. doi:10.3389/fphar.2020.595635
Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and Pain: A Clinical Review. Cannabis Cannabinoid Res. 2017;2(1):96-104. Published 2017 May 1. doi:10.1089/can.2017.001733.
Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980;87(3):222-228. doi:10.1016/s0161-6420(80)35258-5
Potschka H, Bhatti SFM, Tipold A, McGrath S. Cannabidiol in canine epilepsy. Vet J. 2022;290:105913. doi:10.1016/j.tvjl.2022.105913
Georgieva D, Langley J, Hartkopf K, et al. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy Behav. 2023;141:109159. doi:10.1016/j.yebeh.2023.109159
Ducobu J, Sternon J. Le rimonabant (Acomplia), inhibiteur spécifique du système endocannabinoïde [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. J Pharm Belg. 2005;60(3):89-91.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Klaudia Kowalczyk, Patryk Lasek, Natalia Trąbka, Paulina Binkowska, Gabriela Demidowicz, Nina Lasota, Maciej Smerdzyński, Katarzyna Łach, Kinga Ściurka, Kinga Panuciak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 668
Number of citations: 0
